Akèy › Kansè Vezik ki pa envazif miskilè › Lwizyàn
Etid klinik pou Kansè Vezik ki pa envazif miskilè nan Lwizyàn
5 etid pou Kansè Vezik ki pa envazif miskilè ap chèche patisipan nan sit nan Lwizyàn.
Vil nan Lwizyàn
Tèks ofisyèl etid la (Anglè)
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- Mary Bird Perkins Cancer Center - Metairie, Metairie
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07000084A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- Southern Urology, LLC ( Site 0145), Lafayette
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06833073A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- Southern Urology LLC, Lafayette
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06919965Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Southern Urology, Lafayette
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05951179FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Mary Bird Perkins Cancer Center, Baton Rouge
- Ochsner Clinic Foundation, New Orleans
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05614739Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.